Breaking News Instant updates and real-time market news.

CBAY

CymaBay

$9.01

-1.485 (-14.16%)

, ICPT

Intercept

$100.72

-0.07 (-0.07%)

06:07
11/14/18
11/14
06:07
11/14/18
06:07

CymaBay data show superior efficacy to Intercept's, says Piper Jaffray

The additional detail provided by CymaBay (CBAY) yesterday via the 52-week analysis of seladelpar in 34 patients "was indeed solid highlighting a superior efficacy and safety profile" relative to Intercept's (ICPT) Ocaliva, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The data suggest that the ongoing Phase III Enhance study is highly likely to be successful, contends the analyst. He points out that that despite the "clean dataset," some are poking at a numerical increase in bilirubin levels in the 10mg arm. The analyst, however, believes this is clinically insignificant. Van Buren continues to recommend that investors purchase CymaBay shares, believing they are undervalued on the primary biliary cholangitis program alone. He keeps an Overweight rating on the name with a $30 price target.

CBAY

CymaBay

$9.01

-1.485 (-14.16%)

ICPT

Intercept

$100.72

-0.07 (-0.07%)

  • 27

    Nov

CBAY CymaBay
$9.01

-1.485 (-14.16%)

10/15/18
PIPR
10/15/18
NO CHANGE
PIPR
Piper lists names to own in Biopharma after recent selloff
Piper Jaffray's biopharma analyst team highlighted names to own in the Biopharma sector following the recent selloff of the broader market. The firm's ideas include: Adamas Pharmaceuticals (ADMS), Agios Pharmaceuticals (AGIO), Agios Pharmaceuticals (ALNY), Alexion (ALXN), Bluebird Bio (BLUE), BioMarin (BMRN), CymaBay (CBAY), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), Jazz Pharmaceuticals (JAZZ), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and Xencor (XNCR).
08/09/18
PIPR
08/09/18
NO CHANGE
Target $30
PIPR
Overweight
CymaBay price target raised to $30 from $16 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren raised his price target on CymaBay to $30 and kept his Overweight rating, saying he expects the company's cinical progress and additional updates in PBC and NASH to drive its share price higher over the next 12-18 months. The analyst expects the PBC phase 2 data on seladelpar expected in Q4 to be "confirmartory", de-risking the subsequent phase 3 trial. He adds that the phase 2b proof of concept NASH study will hopefully show "clinically meaningful effects based on the preclinical data and differentiated mechanism of action".
06/28/18
RAJA
06/28/18
INITIATION
Target $20
RAJA
Outperform
CymaBay initiated with an Outperform at Raymond James
Raymond James analyst Steven Seedhouse initiated CymaBay with an Outperform and $20 price target.
06/06/18
HCWC
06/06/18
NO CHANGE
Target $23
HCWC
Buy
CymaBay price target raised to $23 from $21 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for CymaBay Therapeutics to $23 saying the company is well positioned to successfully execute its strategy with seladelpar. The analyst reiterates a Buy rating on the shares.
ICPT Intercept
$100.72

-0.07 (-0.07%)

11/05/18
STFL
11/05/18
NO CHANGE
Target $35
STFL
Buy
Stifel bullish on Galmed ahead of Phase 3 NASH trial
Stifel analyst Adam Walsh noted that Galmed (GLMD) announced along with its Q3 earnings report that the Phase 3 ARMOR study of lead product candidate Aramchol will initiate at the end of Q2 or early in Q3 of 2019. Design details aren't finalized, but management guided towards a design similar to Intercept's (ICPT) ongoing pivotal study of OCA in NASH, said Walsh. He remains bullish on Galmed shares heading into the ARMOR study, highlighting that the company's Phase 2b trial showed strong trends on the two NASH regulatory approvable endpoints along with clinically meaningful NASH resolution. Walsh keeps a Buy rating and $35 price target on Galmed shares.
11/01/18
CANT
11/01/18
NO CHANGE
Target $170
CANT
Overweight
Cantor 'very positive' on Intercept shares following recent pullback
Cantor Fitzgerald analyst Alethia Young is "very positive" on shares of Intercept Pharmaceuticals following the recent selloff and views the stock as a top pick over 2019. Ocaliva sales in Q3 were roughly in line with consensus estimates, Young tells investors in a post-earnings research note. She thinks the risk/reward is attractive, with potential upside 130% versus downside risk of 50%, into the Phase 3 NASH readout. The analyst reiterates an Overweight rating on Intercept with a $170 price target.
10/02/18
JEFF
10/02/18
NO CHANGE
Target $135
JEFF
Buy
Jefferies sees Intercept moving higher after 'mixed' Gilead data
Jefferies analyst Michael Yee views Gilead Sciences' (GILD) new six-month nonalcoholic steatohepatitis data as "mixed and undifferentiated." As such, he thinks shares of Intercept Pharmaceuticals (ICPT) probably continue to move higher. The stock is likely to retrace back up into year-end and the first half of 2019 as Street realizes Intercept's Phase III will be positive and de-risked, Yee tells investors in a research note. He says the company has had various competitor Farnesoid X receptor data in Phase I/II read out over the past year or and that these have ended up not too differentiated. This has removed some of the competitive overhang on Intercept, the analyst contends. Yee keeps a Buy rating on the shares with a $135 price target.
10/02/18
10/02/18
DOWNGRADE

Outperform
Intercept downgraded to Outperform on valuation at Raymond James
As previously reported, Raymond James downgraded Intercept to Outperform from Strong Buy and raised its price target to $141 from $126. Analyst Steven Seedhouse said risk/reward is favorable ahead of the pivotal REGENERATE data in 1H 2019, but said some of the binary upside from his original thesis is reflected in shares.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
08/21/19
08/21
14:17
08/21/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$292.08

2.05 (0.71%)

, SPX

S&P 500

$0.00

(0.00%)

14:16
08/21/19
08/21
14:16
08/21/19
14:16
Periodicals
Fed minutes show July cut for insurance for growth, inflation, Bloomberg says »

The interest rate cut…

SPY

SPDR S&P 500 ETF Trust

$292.08

2.05 (0.71%)

SPX

S&P 500

$0.00

(0.00%)

QQQ

Invesco QQQ Trust

$188.29

1.3 (0.70%)

SMH

Market Vectors Semiconductor

$114.29

0.855 (0.75%)

IWM

iShares Trust Russell 2000 Index Fund

$150.29

1.18 (0.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
08/21/19
08/21
14:16
08/21/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:15
08/21/19
08/21
14:15
08/21/19
14:15
General news
FOMC minutes didn't provide strong clues on the direction of rates »

FOMC minutes didn't…

14:15
08/21/19
08/21
14:15
08/21/19
14:15
General news
FX Action: The dollar »

FX Action: The dollar…

WYND

Wyndham Destinations

$42.79

0.21 (0.49%)

14:11
08/21/19
08/21
14:11
08/21/19
14:11
Hot Stocks
Wyndham Destinations to add 140 jobs in Orlando expansion »

Wyndham Destinations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

SPY

SPDR S&P 500 ETF Trust

$292.47

2.44 (0.84%)

, SPX

S&P 500

$0.00

(0.00%)

14:04
08/21/19
08/21
14:04
08/21/19
14:04
General news
Fed minutes show 'couple of participants' would have preferred 50 bps rate cut »

The minutes for the…

SPY

SPDR S&P 500 ETF Trust

$292.47

2.44 (0.84%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Symbol is now VWAGY

$0.00

(0.00%)

, POAHY

Porsche

$0.00

(0.00%)

14:03
08/21/19
08/21
14:03
08/21/19
14:03
Hot Stocks
Porsche acquires minority stake in Israeli startup TriEye »

Volkswagen's (VLKAY)…

VLKAY

Symbol is now VWAGY

$0.00

(0.00%)

POAHY

Porsche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$292.42

2.39 (0.82%)

, SPX

S&P 500

$0.00

(0.00%)

14:02
08/21/19
08/21
14:02
08/21/19
14:02
General news
Fed minutes show July rate cut viewed by 'most' on FOMC as 'recalibration' »

The minutes for the…

SPY

SPDR S&P 500 ETF Trust

$292.42

2.39 (0.82%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$35.06

0.44 (1.27%)

14:01
08/21/19
08/21
14:01
08/21/19
14:01
Hot Stocks
Pfizer says FDA grants XTANDI application priority review »

Astellas Pharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 16

    Sep

TGT

Target

$102.13

16.555 (19.35%)

13:52
08/21/19
08/21
13:52
08/21/19
13:52
Recommendations
Target analyst commentary at Baird »

Target price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

JMIA

Jumia Technologies

$12.43

-2.26 (-15.38%)

13:47
08/21/19
08/21
13:47
08/21/19
13:47
Recommendations
Jumia Technologies analyst commentary at Stifel »

Jumia's report…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

13:45
08/21/19
08/21
13:45
08/21/19
13:45
General news
Breaking General news story  »

FOMC Minutes to be…

AFL

Aflac

$49.66

-2.2 (-4.24%)

13:38
08/21/19
08/21
13:38
08/21/19
13:38
Periodicals
Aflac reiterates review being done of Post channel sales, Bloomberg says »

Aflac reiterated that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,823.96

21.88 (1.21%)

, WMT

Walmart

$112.15

0.03 (0.03%)

13:37
08/21/19
08/21
13:37
08/21/19
13:37
Periodicals
Amazon opens 'largest campus yet' in south Indian city, Bloomberg says »

According to an earlier…

AMZN

Amazon.com

$1,823.96

21.88 (1.21%)

WMT

Walmart

$112.15

0.03 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 25

    Sep

  • 27

    Oct

  • 13

    Nov

  • 14

    Nov

CBL

CBL & Associates

$0.86

0.022 (2.62%)

13:32
08/21/19
08/21
13:32
08/21/19
13:32
Hot Stocks
CBL Properties to pursue measures to cure NYSE rule non-compliance »

CBL Properties announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
08/21/19
08/21
13:25
08/21/19
13:25
Conference/Events
The Food & Drug Law Institute to hold a webinar »

Anthony Anscombe, Partner…

13:25
08/21/19
08/21
13:25
08/21/19
13:25
Conference/Events
FOMC releases minutes from July 30-31, 2019 Policy Meeting »

The Federal Open Market…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
08/21/19
08/21
13:17
08/21/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,195.07

11.64 (0.98%)

, GOOGL

Alphabet Class A

$1,196.08

11.82 (1.00%)

13:16
08/21/19
08/21
13:16
08/21/19
13:16
Hot Stocks
YouTube Premium users can now listen directly within Waze app »

In an earlier blog post,…

GOOG

Alphabet

$1,195.07

11.64 (0.98%)

GOOGL

Alphabet Class A

$1,196.08

11.82 (1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
08/21/19
08/21
13:16
08/21/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHC

Bausch Health

$22.31

1.05 (4.94%)

13:06
08/21/19
08/21
13:06
08/21/19
13:06
Hot Stocks
Bausch Health trades up after VP Humphries buys over $650K in shares »

Bausch Health VP William…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 23

    Sep

FB

Facebook

$185.03

1.27 (0.69%)

, TWTR

Twitter

$42.65

0.355 (0.84%)

13:05
08/21/19
08/21
13:05
08/21/19
13:05
On The Fly
#SocialStocks: New 'Off-Facebook Activity' tool, Argus upgrades Pinterest »

Welcome to…

FB

Facebook

$185.03

1.27 (0.69%)

TWTR

Twitter

$42.65

0.355 (0.84%)

PINS

Pinterest

$36.40

2.05 (5.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

ALXN

Alexion

$113.91

2.49 (2.23%)

13:05
08/21/19
08/21
13:05
08/21/19
13:05
Options
Alexion call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 02

    Oct

  • 19

    Oct

VIOT

Viomi Technology

$9.00

-0.27 (-2.91%)

12:57
08/21/19
08/21
12:57
08/21/19
12:57
Initiation
Viomi Technology initiated at Needham »

Viomi Technology assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.